MedPath

Dopamine Release in the Human Brain Following Alcohol Administration

Phase 1
Completed
Conditions
Heavy Drinking
Interventions
Drug: alcoholic beverage
Drug: non-alcoholic beverage
Registration Number
NCT01638364
Lead Sponsor
Centre for Addiction and Mental Health
Brief Summary

The purpose of this study is to examine whether there is an increase in dopamine levels in the human striatum following an oral administration of alcohol, as has been evidenced in animal models. This will be a Positron Emission Tomography (PET) study using the radiotracer, \[11C\]-(+)-PHNO (11C\]-( + )-4-propyl- 3,4,4a,5,6,10b-hexahydro-2H-naphtho\[1,2-b\]\[1,4\]oxazin-9-ol).

Detailed Description

This will be a within subjects study in 8 heavy drinkers ages 21-45. The within factors will be PET scans following an alcoholic beverage and following a non-alcoholic beverage. Participants will also have a baseline session prior to the scans where they will complete various cognitive tasks and questionnaires. During each PET scan, subjective drug effects as well as heart rate, blood pressure, blood alcohol content and cortisol levels will be collected. The change in PHNO binding potential between the two scan conditions will be the primary outcome measure.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
8
Inclusion Criteria
  • Healthy males and females of any ethnic origin between 21 and 45 years old.
  • Reported consumption of at least two heavy drinking episodes (according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA) criterion of 5 drinks for males or 4 for females) in the past 30 days prior to assessment.
  • Willing and capable to provide written informed consent
  • Good command of the English language
Exclusion Criteria
  • Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) diagnosis of alcohol dependence; receiving treatment for alcohol dependence
  • Taking medications or have any medical condition for which alcohol is contraindicated
  • Any medical condition requiring immediate investigation or treatment
  • Previous head trauma/neurological condition such as clinically significant history of seizure disorder, a history of clinically significant head trauma (i.e., concussion resulting in clinically significant loss of consciousness) or past intracranial surgery
  • Beck Depression Inventory score >16
  • Current active or past suicidal ideation
  • Pregnancy tested by urine and blood screen each PET study day or lactation
  • Current DSM-IV diagnosis of any Axis I psychiatric disorder
  • Regular use of any therapeutic or recreational psychoactive drug use during the last three months (with the exception of nicotine and alcohol) or other substance use disorder (including nicotine)
  • Abnormal body mass (as defined as not within 20% of normal body mass index).
  • Current past or anticipated exposure to radiation exceeding 20 mSv in the last year.
  • Metal implants or paramagnetic objects within the body which may interfere with the magnetic resonance imaging (MRI).
  • Claustrophobia or a history of panic attacks
  • Abnormal clinical laboratory findings including serum creatinine greater than 2.0 mg/dl, abnormal liver function tests, elevated serum bilirubin (more than 1.5 times upper limit of normal), or pre-trial electrocardiogram (EKG) results demonstrating clinical significant abnormality

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
alcoholic beveragealcoholic beverage95% USP alcohol given at a dose of 1.5 g/l of body water mixed with orange juice and tonic water.
non-alcoholic beveragenon-alcoholic beverageOrange juice and tonic water.
Primary Outcome Measures
NameTimeMethod
Change in PHNO Binding Potential2 weeks

Following the injection of the positron-emitting radiotracer \[11C\]-(+)-PHNO, binding of this radiotracer to dopamine receptors (DR) D2/3 will be measured using the PET scanner. As dopamine also binds to DR D2/3, either an increase or decrease in dopamine levels will either decrease or increase PHNO occupancy respectively. \[11C\]-(+)-PHNO binding potential will be measured on two different conditions (alcoholic beverage vs non-alcoholic beverage) on two separate days.

Secondary Outcome Measures
NameTimeMethod
Subjective effects of alcohol2 weeks

During the PET scans, the subjective effects ( Alcohol Urges Scale, Biphasic Alcohol Effects Scale)of alcohol will be assessed at various time points throughout beverage consumption and PET scan.

Objective effects of alcohol2 weeks

During the PET scans, the objective effects of alcohol (blood pressure, heart rate, blood alcohol content, blood cortisol levels) will be assessed at various time points throughout the drink consumption and PET scan.

Trial Locations

Locations (1)

Centre for Addiction and Mental Health

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath